Chromocell Therapeutics Seeks $8.7 Million In Micro-IPO

• Chromocell Therapeutics, a Phase 1 biotech developing a non-addictive pain blocker using a sodium ion channel
• HQ North Brunswick, New Jersey
• https://chromocell.com/

 

Chromocell Therapeutics Corporation has filed for an $8.7 million IPO to develop its treatment for chronic pain conditions.

The company's lead compound is being prepared for a Phase 2a study for erythromelalgia patients with a genetic component.

The global market for erythromelalgia treatment is estimated to reach $3.5 billion by 2032, driving potential growth for Chromocell.

==Maison Solutions (MSS) began trading on the Nasdaq on Thur 5 Oct 23

Maison Solutions Inc. is a fast-growing specialty grocery retailer offering traditional Asian food and merchandise to modern U.S. consumers, particularly to members of Asian-American communities.

• Headquarters: Monterey Park, CA
• Founded: 2019
• maisonsolutionsinc.com